DCGI Approval

Zydus dedicatfigfl g Cadila Healthcare Limited March 5, 202 Listing Department BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai—400 001 Listing Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai—400 051 Re.: Notification Dear Sir / Madam, Code: 532 321 Code: CADILAHC We hereby inform that the Company has received the approval from the Drug Controller General of India (DCGI) for its New Drug Application (NDA) for Saroglitazar for the treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) in India. We request you to bring this news to the notice of the members of the exchange and the investors at large. Thanking you, Yours faithfully, For, CADILA HEALTHCARE LIMITED W05/» DHAVAL N. SONI COMPANY SECRETARY Regd. Ofiice : 'Zydus Corporate Park', Scheme No. 63. Survey No. 536. Khorai {Gandhinagar}, Nr. Vaishnodevi Circle, 8. G. Highway, Ahmedabad 382 481, India. Phone : +91-079-71800000. +91-079-48040000 www.zyduscadila.com CIN :L2423UGJ1995PL0025878

The release as fetched from its publisher. zyduslife.com ↗